JP6818031B2 - モルホリン誘導体の塩、結晶形、その製造方法、これらを含む医薬組成物およびその用途 - Google Patents

モルホリン誘導体の塩、結晶形、その製造方法、これらを含む医薬組成物およびその用途 Download PDF

Info

Publication number
JP6818031B2
JP6818031B2 JP2018534034A JP2018534034A JP6818031B2 JP 6818031 B2 JP6818031 B2 JP 6818031B2 JP 2018534034 A JP2018534034 A JP 2018534034A JP 2018534034 A JP2018534034 A JP 2018534034A JP 6818031 B2 JP6818031 B2 JP 6818031B2
Authority
JP
Japan
Prior art keywords
morpholine derivative
shows
morpholine
tartrate
plot
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018534034A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019500385A5 (cg-RX-API-DMAC10.html
JP2019500385A (ja
Inventor
广新 夏
广新 夏
建樹 謝
建樹 謝
国慧 賈
国慧 賈
建生 韓
建生 韓
上田　直子
直子 上田
徹 飯嶋
徹 飯嶋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Pharmaceuticals Holding Co Ltd
Original Assignee
Shanghai Pharmaceuticals Holding Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Pharmaceuticals Holding Co Ltd filed Critical Shanghai Pharmaceuticals Holding Co Ltd
Publication of JP2019500385A publication Critical patent/JP2019500385A/ja
Publication of JP2019500385A5 publication Critical patent/JP2019500385A5/ja
Application granted granted Critical
Publication of JP6818031B2 publication Critical patent/JP6818031B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/33—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems
    • C07C309/34—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems formed by two rings
    • C07C309/35—Naphthalene sulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/42—Separation; Purification; Stabilisation; Use of additives
    • C07C51/43—Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/08—Acetic acid
    • C07C53/10—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2018534034A 2015-12-29 2016-12-29 モルホリン誘導体の塩、結晶形、その製造方法、これらを含む医薬組成物およびその用途 Active JP6818031B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201511016783 2015-12-29
CN201511016783.3 2015-12-29
PCT/CN2016/112966 WO2017114456A1 (zh) 2015-12-29 2016-12-29 吗啉衍生物的盐及其晶型、其制备方法及药物组合物、用途

Publications (3)

Publication Number Publication Date
JP2019500385A JP2019500385A (ja) 2019-01-10
JP2019500385A5 JP2019500385A5 (cg-RX-API-DMAC10.html) 2019-09-12
JP6818031B2 true JP6818031B2 (ja) 2021-01-20

Family

ID=59224612

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018534034A Active JP6818031B2 (ja) 2015-12-29 2016-12-29 モルホリン誘導体の塩、結晶形、その製造方法、これらを含む医薬組成物およびその用途

Country Status (11)

Country Link
US (1) US10519150B2 (cg-RX-API-DMAC10.html)
EP (1) EP3398946B1 (cg-RX-API-DMAC10.html)
JP (1) JP6818031B2 (cg-RX-API-DMAC10.html)
CN (3) CN113816951B (cg-RX-API-DMAC10.html)
DK (1) DK3398946T3 (cg-RX-API-DMAC10.html)
ES (1) ES2918674T3 (cg-RX-API-DMAC10.html)
HU (1) HUE059444T2 (cg-RX-API-DMAC10.html)
PL (1) PL3398946T3 (cg-RX-API-DMAC10.html)
PT (1) PT3398946T (cg-RX-API-DMAC10.html)
TW (1) TWI705065B (cg-RX-API-DMAC10.html)
WO (1) WO2017114456A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022047730A1 (en) * 2020-09-04 2022-03-10 Shanghai Pharmaceuticals Holding Co., Ltd. Methods to treat inflammatory bowel disease
KR102898913B1 (ko) * 2020-09-04 2025-12-10 상하이 파마슈티컬스 홀딩 컴퍼니 리미티드 질소 함유 포화 헤테로사이클릭 화합물의 응용
CN116425677B (zh) * 2022-01-11 2026-04-14 苏州恩华生物医药科技有限公司 氨基环丁烷衍生物的盐、其晶型及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL150524A0 (en) * 2000-01-07 2003-02-12 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
EP2687518B1 (en) * 2011-03-16 2017-11-01 Mitsubishi Tanabe Pharma Corporation Nitrogen-containing saturated heterocyclic compound
JP5764628B2 (ja) * 2012-09-14 2015-08-19 田辺三菱製薬株式会社 医薬組成物
WO2014042263A1 (ja) * 2012-09-14 2014-03-20 田辺三菱製薬株式会社 新規レニン阻害薬

Also Published As

Publication number Publication date
CN113816951A (zh) 2021-12-21
CN106928218B (zh) 2021-08-03
ES2918674T3 (es) 2022-07-19
CN106928218A (zh) 2017-07-07
EP3398946A1 (en) 2018-11-07
PL3398946T3 (pl) 2022-10-10
TWI705065B (zh) 2020-09-21
PT3398946T (pt) 2022-08-09
WO2017114456A1 (zh) 2017-07-06
US10519150B2 (en) 2019-12-31
US20190016718A1 (en) 2019-01-17
EP3398946A4 (en) 2019-08-28
EP3398946B1 (en) 2022-05-04
TW201722950A (zh) 2017-07-01
JP2019500385A (ja) 2019-01-10
CN113816951B (zh) 2022-09-27
HUE059444T2 (hu) 2022-11-28
CN113816952A (zh) 2021-12-21
DK3398946T3 (da) 2022-08-08

Similar Documents

Publication Publication Date Title
ES3025633T3 (en) New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
JP7407740B2 (ja) Ｔｌｒ７／ｔｌｒ８阻害剤の結晶形態
TW202335670A (zh) ｛［５—（３—氯苯基）—３—羥基吡啶—２—羰基］胺基｝乙酸之固體型式，其組合物及用途
JP2007169288A (ja) レボフロキサシンおよびその形態の調製
JP2018501289A (ja) ネラチニブマレイン酸塩の新規な結晶形及びその製造方法
KR20170057441A (ko) Jak 억제제의 바이설페이트의 결정형 및 이의 제조방법
JP7528060B2 (ja) スルホンアミド構造キナーゼ阻害剤の新規塩酸塩形態
MX2007012605A (es) Formas cristalinas novedosas de armodafinil y preparacion de ellas.
JP2019500385A (ja) モルホリン誘導体の塩、結晶形、その製造方法、これらを含む医薬組成物およびその用途
JP2012512145A (ja) フリバンセリンの結晶性の塩形態
TW200900392A (en) Novel crystalline bepotastine metal salt hydrate, method for preparing same, and pharmaceutical composition comprising same
EP2315764A2 (en) Crystalline form of sunitinib and processes for its preparation
JP2019500385A5 (cg-RX-API-DMAC10.html)
US20200283381A1 (en) Solid state forms of elafibranor
JP6577938B2 (ja) セフジトレンピボキシルの新規結晶形態およびその製造方法
JP2014518236A (ja) ６−（ピペリジン−４−イルオキシ）−２ｈ−イソキノリン−１−オン塩酸塩の多形体
WO2012119653A1 (en) Process for making crystalline form a of linezolid
JP5017274B2 (ja) Ｓ−オメプラゾールストロンチウム塩またはその水和物、その製造方法、及びこれを含む医薬組成物
JP2007514744A (ja) ２，３−ジメチル−８−（２，６−ジメチルベンジルアミノ）−Ｎ−ヒドロキシエチル−イミダゾ［１，２−ａ］ピリジン−６−カルボキシアミドメシラート塩の新規な結晶形
CN121241043A (zh) 埃维酰胺的晶型
JP2013227298A (ja) （１ｓ）−１，５−アンヒドロ−１−［５−（４−エトキシベンジル）−２−メトキシ−４−メチルフェニル］−１−チオ−ｄ−グルシトールのｅ形結晶及びその製造方法
WO2017035170A1 (en) Solid state forms of cediranib maleate

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20190304

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190304

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190802

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190802

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200611

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200707

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201006

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20201208

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201225

R150 Certificate of patent or registration of utility model

Ref document number: 6818031

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250